{"url_path":"/sec/fblg/8-k/2026-06-29/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-29","source_url":"https://www.sec.gov/Archives/edgar/data/1958777/0001193125-26-288468-index.html","accession_number":"0001193125-26-288468","cik":"0001958777","ticker":"FBLG","issuer_name":"FibroBiologics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1958777/0001193125-26-288468-index.html","primary_entity_key":"0001958777","primary_entity_name":"FibroBiologics, Inc."},"word_count":132,"has_tables":true,"body_markdown":"Item 9.01 Financial Statements and Exhibits.\n\n \n\nExhibit No.\n\nDescription\n\n[10.1](fblg-ex10_1.htm)\n\n[Form of Securities Purchase Agreement, dated June 25, 2026, between FibroBiologics, Inc. and the purchaser named](fblg-ex10_1.htm)\n\n \n\n \n\ntherein\n\n[10.2](fblg-ex10_2.htm)\n\n \n\n[Form of Registration Rights Agreement, dated June 25, 2026, between FibroBiologics, Inc. and the purchaser named therein](fblg-ex10_2.htm)\n\n[4.1](fblg-ex4_1.htm)\n\n[Form of Pre-Funded Warrant](fblg-ex4_1.htm)\n\n[4.2](fblg-ex4_2.htm)\n\n[Form of Warrants](fblg-ex4_2.htm)\n\n[4.3](fblg-ex4_3.htm)\n\n[Form of Placement Agent Warrant](fblg-ex4_3.htm)\n\n[99.1](fblg-ex99_1.htm)\n\n[Press Release dated June 26, 2026](fblg-ex99_1.htm)\n\n[99.2](fblg-ex99_2.htm)\n\n[Press Release dated June 29, 2026](fblg-ex99_2.htm)\n\n104\n\nCover Page Interactive Data File (formatted in Inline XBRL).\n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \n\nFibroBiologics, Inc.\n\n \n\n \n\n \n\n \n\nDate:\n\nJune 29, 2026\n\nBy:\n\n/s/ Pete O'Heeron\n\n \n\n \n\n \n\nName: Pete O'Heeron\nTitle: Chief Executive Officer"}